Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

• Main Authors: Fengze Sun (Author), Dawei Wang (Author), Aina Liu (Author), Tianqi Wang (Author), Dongxu Zhang (Author), Huibao Yao (Author), Kai Sun (Author), Zhongbao Zhou (Author), Guoliang Lu (Author), Jitao Wu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Programmed death 1 (PD-1) inhibitors-tislelizumab, toripalimab, camrelizumab, and sintilimab-are used for advanced urothelial carcinoma (UC) in China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors have been poorly reported for advanced UC.Methods: We reviewed 11...